Highlight Articles

Featured image
NRx Pharmaceuticals Identifies Significantly Higher Likelihood of Surviving and Recovering from Critical COVID-19 in ZYESAMI® (aviptadil) Treated Patients Previously Administered Remdesivir

Analysis was conducted in the subgroup of ZYESAMI- and placebo-treated patients who were previously treated with remdesivir in the COVID-AIV trial representing approximately 70 percent of the study populationAnalysis was […]

Continue Reading
Featured image
NRx Pharmaceuticals Notes New Data on BriLife® COVID-19 Vaccine Effectiveness Against Delta Variant Posted by Israel Institute for Biological Research

Analysis of Blood Samples from Patients who Responded to the BriLife® Vaccine During Phase 2 Trial Suggests that the Same Level of Response was Seen Against the Delta Variant as […]

Continue Reading
3PLAccelerated RecoveryACTIV-3ACTIV-3bActive3bAcute Respiratory Distress SyndromeAcute Respiratory FailureAdaptive Platform Trial DesignAnthony S Fauci MDARDSAviptadilAvitpadilBARDABig Rock PartnersBipolar DepressionBNP ParibasBoosterBreakthrough Therapy DesignationBRilifeBRILife®BTDCAHCardinal HealthCH HealthChaim HurvitzCheddar NewsClinical TrialsClosing BellCOID-19Commercial ForumlationCompassionate CareCovid-19COVID-19 SurvivalCritical COVID-19CromosCytokine IL-6Cytokine StormCytokinesData Safety Monitoring BoardDelta VariantDenk PharmaDisease preventionDisease prevention & Control SummitDr YoDr. Sami SaidDry-powder InhalerDSMBEAPEkaterine TikaradzeEmegency Use AuthorizationEmergency UseEmergency Use Authorizationerectile dysfunctionEUAEuropean QPExpanded AccessFast TrackFDAFDA EmeFDA Emergency Use AuthorizationFDA Module 3Fox BusinessGeorgiaGeorgia Society of PhysiciansGeorgian Ministry of HealthGILDGileadGovernment of LuxembourgH.C. Wainwright & Co.HC WainwrightHC Wainwright Annual Global Investment ConferenceHigh Flow NasalHoustonHouston MethodistHouston Methodist JC Walkter Jr Transplant CenterI-Spyi24 NewsICUIIBRIL-6 CytokineInhaled AviptadilIQVIQVIAiSpyIsraelIsrael Institute of Biological ResearchIV ZYESAMI®J. Georges YoussefJ&JJihad Georges YoussefJihad Georges Youssef MDJihad Geroges YoussefJournal of Infectious Diseases and TreatmentLuxembourgLuxembourg Ministry of the EconomyMannkindMDMNKDMolnupiravirNASDAQNation of GeorgiaNational Institutes of HealthNDA ZyesamiNehpron PharmaceuticalsNephronNephron PharmaceuticalsNIAIDNIHNRx Business UpdateNRx EarningsNRX-100NRX-100/101NRX-101NRXPOrphan Drug DesignationPeptidesPharmacovigilancePrivate PlacementProf Jonathan JavittProf Jonathan Javitt MD MPHPTSDQ2 EarningsQ3 Finaincial ResultsQP AuditorQP DeclarationQuantum Leap HealthcareRemdesivirRespiratory Distress RatioRespiratory FailureRichard G Lugar Center for Public HealthRichard Luger CenterRIght to TryRLF-100RLF-100_002RTTSami SaidSar-CoV-2Sars-CoV-2Sever COVID-19Suicidal DepressionTechnosphereTESICOUCIUkraineUS Food and Drug AdministrationUSFDAVaccineVaccine TrialVasoactive Intestinal PeptideVekluryVIPVirologyZYESAMIZYESAMI®ZYESAMI™ZYESAMI™ INDZysamiZYSAMI®ZYSAMI® (aviptadil)